Login to Your Account


Add back or not add back? Obseva: Both options good as UF, endo trials continue

By Randy Osborne
Staff Writer

Thursday, March 30, 2017

A long half-life, high bioavailability and no food affect – plus the prospect for add-back hormone therapy or not – may distinguish Geneva-based Obseva SA's gonadotropin-releasing hormone (GnRH) therapy for uterine fibroids (UF) and endometriosis, CEO Ernest Loumaye told BioWorld Today. "The beauty of this class is its capacity to suppress estradiol in a dose-dependent manner," he said. "Where we are different is in the pharmacokinetic [PK] profile of OBE2109 and how we are developing it."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription